Caregiver Alert - Important Update on Namenda (Memantine)

Forest Laboratories, Inc. has announced that it plans to discontinue the sale of NAMENDA® (memantine HCl) 5 mg and 10 mg tablets effective August 15, 2014. +Alzheimer's Reading Room As far as I can tell more than sixty percent (60 percent) of all Alzheimer's patients are currently being treated with the combination of Namenda and Aricept (Donepezil, or another acetylcholinesterase inhibitor).Beginning in August, Forest Laboratories plans to discontinue Namenda tablets, and instead will be offering a new formulation NAMENDA XR®.So the news that follows in the press release below should be read carefully and shared in support groups worldwide.I would suggest that Alzheimer's caregivers bring this information to their physician or neurologist now, and start discussing the implications of this change if you have not already done this. I am not a doctor but I have written many times that I beleive my mother did benefit from being on the combination therapy (Arciept and Namenda). See the related content below.Subscribe to the Alzheimer's Reading RoomEmail: Forest Laboratories to Discontinue NAMENDA® Tablets, Focus on Once-Daily NAMENDA XR®Decision Supported by Positive Reception of NAMENDA XR by Physicians, Patients, and CaregiversForest Laboratories, Inc. (NYSE:FRX), a leading, fully integrated, specialty pharmaceutical company largely focused on the United States market, today announced that it plans to discontinue the sale of NAMENDA® (memantine HCl) 5 mg and 10 mg table...
Source: Alzheimer's Reading Room, The - Category: Dementia Authors: Source Type: blogs